Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas
| Autor: | Tracy Kerby, Geoffrey B. Mccowage, Margaret Duncan-Brown, Herbert E. Fuchs, O. Michael Colvin, Elizabeth S. Stewart, David M. Ashley, Albert Moghrabi, Darryl C. Longee, Roger E. McLendon, Robert D. Tien, Lee Ferrell, Lisa Meier, Joanne Kurtzberg, Henry S. Friedman |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Cancer Research
Chemotherapy Pathology medicine.medical_specialty Cyclophosphamide business.industry medicine.medical_treatment Neutropenia medicine.disease Gastroenterology Nitrogen mustard Central nervous system disease chemistry.chemical_compound Oncology chemistry Internal medicine Glioma Pediatrics Perinatology and Child Health Toxicity medicine business Anaplastic astrocytoma medicine.drug |
| Zdroj: | Medical and Pediatric Oncology. 30:75-80 |
| ISSN: | 1096-911X 0098-1532 |
| Popis: | Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was given at a dose of 2 g/m 2 daily for 2 days at 4-week intervals. Toxicity consisted of grade IV neutropenia and thrombocytopenia in 95% and 48% of cycles, respectively. There were no cyclophosphamide-related cardiac, pulmonary, or urothelial toxicities observed. Four of 10 patients with newly diagnosed disease demonstrated responses (three complete and one partial responses ; one CR was only of 2 months duration). None of the seven patients with recurrent tumors demonstrated a response. We conclude that high-dose cyclophosphamide warrants further evaluation in children with newly diagnosed malignant glioma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text